Clinical Trials

Takeda Pharmaceutical announced that its purified, inactivated, alum-adjuvanted, whole Zika virus vaccine candidate (TAK-426) has progressed into a Phase 1 clinical trial, approximately…
Read More...

Catalyst Pharmaceuticals announced positive top-line results from a second Phase 3 clinical trial (LMS-003) of Firdapse® (amifampridine phosphate tablets equivalent to 10 mg…
Read More...

Millendo Therapeutics announced positive topline results from a Phase 2 proof-of-concept study of ATR-101 in classic congenital adrenal hyperplasia (CAH), a rare inherited endocrine…
Read More...

Janssen Research & Development, LLC (Janssen) announced positive results from a randomized, placebo-controlled Phase 2 study investigating the anti-interleukin (IL)-12/23 monoclonal…
Read More...

Stealth BioTherapeutics (Stealth) announced the initiation of MMPOWER-3, a Phase 3 study evaluating the efficacy and safety of daily subcutaneous injections of elamipretide in patients…
Read More...

Otsuka Pharmaceutical announced detailed results from the Phase 3 REPRISE trial of tolvaptan in patients with autosomal dominant polycystic kidney disease (ADPKD). Trial results…
Read More...

AstraZeneca and its global biologics research and development arm, MedImmune, today announced the top-line results of the Phase III STRATOS 2 and TROPOS trials for tralokinumab, an…
Read More...

Impel NeuroPharma announced that the first patient was dosed in the recently-initiated Phase 1 clinical trial of INP104 for acute migraine headache. INP104 is a novel dihydroergotamine…
Read More...

Incyte Corporation and MedImmune, AstraZeneca’s  global biologics research and development arm, announced the expansion of their clinical collaboration. As part of the agreement, the…
Read More...

Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced that the pivotal phase 3 placebo-controlled ENLIVEN (NCT02371369) study of pexidartinib met its primary…
Read More...

Ortek Therapeutics announced that the Ortek ECD™ received 510(k) clearance from the U.S. Food and Drug Administration. The ECD is a patented lightweight tabletop device designed as an…
Read More...

Ionis Pharmaceuticals, Inc. announced that it has initiated a Phase 1/2a clinical study of IONIS-MAPTRx in patients with mild Alzheimer's disease (AD). Ionis earned a $10 million…
Read More...

Flex Pharma announced that, under its open investigational new drug (IND) application, the Company has initiated a Phase 2 randomized, controlled, double-blinded, parallel design trial…
Read More...

Otsuka Pharmaceutical and Lundbeck announce that patient enrollment has been initiated in two global Phase 3 clinical trials to evaluate brexpiprazole for the treatment of patients with…
Read More...

BioTime reported that an investigator-led clinical trial has successfully treated its first patient in a study of Premvia as a carrier for stromal vascular fraction cells (SVF) for the…
Read More...

Izun Pharmaceuticals Corporation announced that the results from a recently completed double blind, Phase 2 clinical study in oral mucositis indicated promising positive outcomes for…
Read More...

Titan Pharmaceuticals announced that the first patient has been treated in a Phase 1/2 trial of the company's ropinirole implant intended for the treatment of the signs and symptoms of…
Read More...

Kaleido Biosciences announced an agreement with CoreBiome, a genomics platform company focused on accelerating microbiome innovation with expert genomics and big-data analytics, to…
Read More...

The U.S. Food and Drug Administration announced that it has awarded 15 new clinical trial research grants totaling more than $22 million over the next four years to boost the…
Read More...

Therapix Biosciences announced that it has entered into an exclusive agreement with Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and…
Read More...